We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Gilead Draws Complete Response Letter for Rheumatoid Arthritis Drug
Gilead Draws Complete Response Letter for Rheumatoid Arthritis Drug
Gilead Sciences has received a complete response letter (CRL) from the FDA for its potential blockbuster rheumatoid arthritis treatment filgotinib, calling for more data from ongoing studies.